Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme

被引:20
|
作者
Masuyer, Geoffrey [1 ]
Douglas, Ross G. [2 ,3 ]
Sturrock, Edward D. [2 ,3 ]
Acharya, K. Ravi [1 ]
机构
[1] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England
[2] Univ Cape Town, Dept Integrat Biomed Sci, ZA-7935 Observatory, South Africa
[3] Univ Cape Town, Inst Infect Dis & Mol Med, ZA-7935 Observatory, South Africa
来源
SCIENTIFIC REPORTS | 2015年 / 5卷
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
ASPARTYL-LYSYL-PROLINE; TERMINAL CATALYTIC DOMAIN; 2; ACTIVE-SITES; N-DOMAIN; CRYSTAL-STRUCTURE; KININASE-II; INHIBITOR; PEPTIDE; FIBROSIS; SPECIFICITY;
D O I
10.1038/srep13742
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Angiotensin-I converting enzyme (ACE) is a zinc dipeptidylcarboxypeptidase with two active domains and plays a key role in the regulation of blood pressure and electrolyte homeostasis, making it the principal target in the treatment of cardiovascular disease. More recently, the tetrapetide N-acetylSer- Asp-Lys-Pro (Ac-SDKP) has emerged as a potent antifibrotic agent and negative regulator of haematopoietic stem cell differentiation which is processed exclusively by ACE. Here we provide a detailed biochemical and structural basis for the domain preference of Ac-SDKP. The high resolution crystal structures of N-domain ACE in complex with the dipeptide products of Ac-SDKP cleavage were obtained and offered a template to model the mechanism of substrate recognition of the enzyme. A comprehensive kinetic study of Ac-SDKP and domain co-operation was performed and indicated domain interactions affecting processing of the tetrapeptide substrate. Our results further illustrate the molecular basis for N-domain selectivity and should help design novel ACE inhibitors and Ac-SDKP analogues that could be used in the treatment of fibrosis disorders.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] SELECTIVITY OF CONVERTING-ENZYME INHIBITORS FOR ANGIOTENSIN-I VERSUS BRADYKININ HYDROLYSIS REACTIONS
    BROOKS, RR
    MILLER, KE
    JONES, SM
    BURNS, RH
    HUANG, CT
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1990, 79 (05) : 384 - 388
  • [22] Dietary Potassium Downregulates Angiotensin-I Converting Enzyme, Renin, and Angiotensin Converting Enzyme 2
    Vio, Carlos P.
    Gallardo, Pedro
    Cespedes, Carlos
    Salas, Daniela
    Diaz-Elizondo, Jessica
    Mendez, Natalia
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [23] Synthetic Peptides as Structural Maquettes of Angiotensin-I Converting Enzyme Catalytic Sites
    Spyranti, Zinovia
    Galanis, Athanassios S.
    Pairas, George
    Spyroulias, Georgios A.
    Manessi-Zoupa, Evy
    Cordopatis, Paul
    BIOINORGANIC CHEMISTRY AND APPLICATIONS, 2010, 2010
  • [24] ELEVATED SERUM ANGIOTENSIN-I CONVERTING ENZYME IN SARCOIDOSIS
    FANBURG, BL
    SCHOENBERGER, MD
    BACHUS, B
    SNIDER, GL
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1976, 114 (03): : 525 - 528
  • [25] A RAPID AUTOMATED PROCEDURE FOR ANGIOTENSIN-I CONVERTING ENZYME
    CHRISTOPHER, CW
    JAYNES, PK
    CHOU, PP
    SEEMILLER, BS
    CLINICAL CHEMISTRY, 1985, 31 (06) : 1003 - 1003
  • [26] CITATION-CLASSIC - ANGIOTENSIN-I CONVERTING ENZYME
    ERDOS, EG
    CURRENT CONTENTS/LIFE SCIENCES, 1986, (18): : 18 - 18
  • [27] INHIBITORS OF THE ANGIOTENSIN-I CONVERTING ENZYME AS ANTIHYPERTENSIVE DRUGS
    VANZWIETEN, PA
    DEJONGE, A
    TIMMERMANS, PBMWM
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1983, 5 (05) : 197 - 204
  • [28] ANGIOTENSIN-I CONVERTING ENZYME FROM RABBIT PLASMA
    UEDA, E
    KOKUBU, T
    AKUTSU, H
    HIWADA, K
    ITO, T
    YAMAMURA, Y
    JAPANESE CIRCULATION JOURNAL, 1971, 35 (10): : 1223 - &
  • [29] IMMUNOLOGICAL ANALYSES OF VASCULAR ANGIOTENSIN-I CONVERTING ENZYME
    WARD, PE
    SHERIDAN, MS
    FEDERATION PROCEEDINGS, 1982, 41 (05) : 1647 - 1647
  • [30] PEPTIDE INHIBITORS OF PULMONARY ANGIOTENSIN-I CONVERTING ENZYME
    SANDER, GE
    WEST, DW
    HUGGINS, CG
    BIOCHIMICA ET BIOPHYSICA ACTA, 1971, 242 (03) : 662 - +